A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: LY3372689
DRUG: LY3372689
DRUG: Placebo

Sponsor

Eli Lilly and Company